A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)

PHASE2CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

April 30, 2001

Study Completion Date

July 31, 2003

Conditions
Prostatic Intraepithelial Neoplasia
Interventions
DRUG

GTX-006 (Acapodene)

Trial Locations (25)

10032

Columbia University, New York

10305

Private Practice, Staten Island

10801

Clinical Research of Westchester, New Rochelle

11706

Medical & Clinical Research Associates, Bay Shore

17604

Urology Associates of Lancaster, Lancaster

19004

Urologic Surgery, P.C, Bala-Cynwyd

20850

Mid Atlantic Clinical Research, Rockville

27103

Salem Research Group, Inc., Winston-Salem

30328

Sandy Springs Urology, P.C., Atlanta

32806

Dr. Byron Hodge, Orlando

33180

South Florida Medical Research, Aventura

34474

The Urology Center of Florida Inc., Ocala

UroSearch, Ocala

34748

UroSearch, Leesburg

35801

Private Practice, Huntsville

45212

Tri-State Urologic Services, Cincinnati

46202

Wishard Memorial Hospital, Indianapolis

72211

Arkansas Urology Associates, Little Rock

78229

Urology San Antonio Research, San Antonio

83814

North Idaho Urology, Couer D'Alene

89109

Private Practice, Las Vegas

98104

Seattle Urological Associates, Seattle

98431

Madigan Army Medical Center, Tacoma

33612-9497

H. Lee Moffitt Cancer Center, Tampa

02162

Newton Wellesley Urology, Newton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GTx

INDUSTRY

NCT00028353 - A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN) | Biotech Hunter | Biotech Hunter